Home/Investors/Omega Funds

Omega Funds

Biotech Investor · 7 portfolio companies

Portfolio

7

Combined Value

$116.6M

Focus Areas

15

Top Stage

Phase 2

Investment Focus

Oncology Urology Immunology Rare Disease Allergy Metabolic Disorders Neurology Immunological Diseases Autoimmune Diseases Inflammatory Diseases Alopecia Areata Parkinson's Disease Alzheimer's Disease Dementia with Lewy Bodies Neurodegenerative Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
enGene	Phase 2/3	$116.6M	Oncology, Urology
IgGenix	phase-2	—	Immunology, Rare Disease
Pretzel Therapeutics	preclinical	—	Rare Disease, Metabolic Disorders
ARTBIO	Phase 2	—	Oncology
ImageneBio	Phase 2	—	Immunological Diseases, Autoimmune Diseases
Vanqua Bio	Pre-clinical	—	Parkinson's Disease, Alzheimer's Disease
IFM Therapeutics (2)	Phase 2	—	Oncology, Inflammatory Diseases

Frequent Co-Investors

OrbiMed2 shared Atlas Venture2 shared Frazier Life Sciences1 shared Sofinnova Investments1 shared Alexandria Venture Investments1 shared Sectoral Asset Management1 shared F-Prime Capital1 shared Polaris Partners1 shared